Zymeworks (ZYME) Completes Theravance Biopharma Acquisition, Integrates YUPELRI into Portfolio

· gurufocus.com

On September 28, 2026, Zymeworks Inc (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI (revefenacin) to its

On September 28, 2026, Zymeworks Inc (NASDAQ: ZYME) finalized its acquisition of Theravance Biopharma, adding the respiratory drug YUPELRI (revefenacin) to its ...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI